Form 8-K

8-K — AbCellera Biologics Inc.

Accession: 0001703057-26-000044

Filed: 2026-08-05

Period: 2026-08-05

CIK: 0001703057

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Results of Operations and Financial Condition

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — abcl-20260805.htm (Primary)

EX-99.1 (q22026earningspressrelease.htm)

EX-99.2 (a2026q2fybusinessupdatea.htm)

GRAPHIC (a2026q2fybusinessupdatea001.jpg)

GRAPHIC (a2026q2fybusinessupdatea002.jpg)

GRAPHIC (a2026q2fybusinessupdatea003.jpg)

GRAPHIC (a2026q2fybusinessupdatea004.jpg)

GRAPHIC (a2026q2fybusinessupdatea005.jpg)

GRAPHIC (a2026q2fybusinessupdatea006.jpg)

GRAPHIC (a2026q2fybusinessupdatea007.jpg)

GRAPHIC (a2026q2fybusinessupdatea008.jpg)

GRAPHIC (a2026q2fybusinessupdatea009.jpg)

GRAPHIC (a2026q2fybusinessupdatea010.jpg)

GRAPHIC (a2026q2fybusinessupdatea011.jpg)

GRAPHIC (a2026q2fybusinessupdatea012.jpg)

GRAPHIC (a2026q2fybusinessupdatea013.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: abcl-20260805.htm · Sequence: 1

abcl-20260805

0001703057falseVancouverBC00017030572026-08-052026-08-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

__________________________________________

FORM 8-K

__________________________________________

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): August 5, 2026

__________________________________________

AbCellera Biologics Inc.

(Exact name of registrant as specified in its charter)

__________________________________________

British Columbia 001-39781 Not Applicable

(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification Number)

150 W 4th Avenue

Vancouver, BC

V5Y 1G6

(Address of registrant’s principal executive office) (Zip code)

(604) 559-9005

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

__________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading symbol(s) Name of each exchange on which registered

Common shares ABCL The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02 Results of Operations and Financial Condition

On August 5, 2026, AbCellera Biologics Inc. (the “Company”), issued a press release announcing its financial and operational results for the quarter ended June 30, 2026. A copy of the press release is furnished herewith as Exhibit 99.1.

Item 7.01 Regulation FD

In connection with its earnings call on August 5, 2026, to discuss its results for the quarter ended June 30, 2026, the Company will utilize a corporate presentation, a copy of which is furnished herewith as Exhibit 99.2.

The information in Items 2.02 and 7.01 of this Form 8-K (including the exhibits attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall such information be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise stated in such filing.

Item 9.01 Financial Statements and Exhibits

(d)Exhibits

Exhibit

No. Description

99.1

Press Release issued by AbCellera Biologics Inc. on August 5, 2026.

99.2

Corporate Presentation.

104 Cover Page Interactive Data File (embedded as Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 5, 2026 ABCELLERA BIOLOGICS INC.

By: /s/ Carl L. G. Hansen

Carl L. G. Hansen, Ph.D.

Chief Executive Officer and Director

(Principal Executive Officer)

EX-99.1

Filename: q22026earningspressrelease.htm · Sequence: 2

Document

NEWS RELEASE

AbCellera Reports Q2 2026 Business Results

8/5/2026

VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today announced financial results for the second quarter of 2026. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.

“Last quarter we completed enrollment for the Phase 2 study of ABCL635, and we expect to announce top-line data very soon,” said Carl Hansen, Ph.D., founder and CEO of AbCellera. “Since our last business update we signed two new collaborations, one with Jazz and one with Vertex, that leverage our T-cell engager platform to advance programs into the clinic and are adding over $100 million in upfront cash to our balance sheet.”

Q2 2026 Business Summary and Program Updates

●ABCL635 top-line data readout from the Phase 2 trial expected in August 2026.

●ABCL386 and ABCL688 are progressing through IND-enabling activities.

●Announced collaboration with Jazz Pharmaceuticals plc to discover and develop next-generation T-cell engagers (TCEs) for multiple gastrointestinal cancers and other solid tumors. AbCellera is receiving $84 million in total upfront payments, with $56 million for the first two research programs and $28 million for a third program, which will initiate within 12 months. AbCellera is eligible to receive up to $792 million per program in option fees and development, regulatory, and commercial sales milestone payments along with tiered royalties on net sales ranging from mid-single digits to low double digits.

●Completed dosing for the Phase 1 study of ABCL575, with top-line data readout expected in Q4 2026.

●Announced the appointments of Dr. Victor Sandor and Dr. Lynn Seely as independent directors to AbCellera’s board of directors.

●Generated a net loss of $55.4 million, compared to a net loss of $34.7 million in Q2 2025.

●Ended the quarter with over $565 million in total cash balances and marketable securities, providing over $675 million in total available liquidity to execute on AbCellera’s strategy.

Subsequent Event

●On July 29, 2026 announced a collaboration with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific TCEs for autoimmune diseases and other conditions. AbCellera will receive $28 million in total

upfront payments and is eligible to receive preclinical, development, regulatory, and commercial milestone payments, along with tiered royalties on net sales.

Discussion of Q2 2026 Financial Results

●Revenue – Total revenue was $4.1 million, compared to $17.1 million in Q2 2025.

●Research & Development (R&D) Expenses – R&D expenses were $46.0 million, compared to $39.2 million in Q2 2025.

●Sales, General, & Administrative (SG&A) Expenses – SG&A expenses were $13.9 million, compared to $22.0 million in Q2 2025.

●Net Loss – Net loss of $55.4 million, or $(0.18) per share on a basic and diluted basis, compared to net loss of $34.7 million, or $(0.12) per share on a basic and diluted basis, in Q2 2025.

●Available Liquidity – over $565 million in total cash balances and marketable securities, and $110 million in available non-dilutive government funding, bringing total available liquidity to over $675 million to execute on AbCellera's strategy.

Business Metrics

At the end of Q2 2026, partners led 35 programs that AbCellera believes to be progressing and where AbCellera holds a downstream stake (down from 44 on December 31, 2025). In total, AbCellera held downstream stakes in 12 molecules in the clinic understood to be progressing on June 30, 2026.

Conference Call and Webcast

AbCellera will host a conference call and live webcast to discuss these results today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time).

The live webcast of the earnings conference call can be accessed on the Events and Presentations section of AbCellera’s Investor Relations website. A replay of the webcast will be available through the same link following the conference call.

About AbCellera Biologics Inc.

AbCellera (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody-based medicines in the areas of endocrinology, women’s health, immunology, oncology, and more. For more information, please visit www.abcellera.com.

AbCellera Forward-Looking Statements

This document contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this document other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, plans, objectives

for future operations, and the evaluation of our available liquidity to execute on our strategy (including our ability to access our reimbursement based R&D government contributions). The use of certain data derived from cross-study comparisons are not based on any head-to-head clinical trials. Cross-study comparisons are inherently limited and may suggest misleading similarities and differences and are presented for informational purposes. In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.

AbCellera Biologics Inc.

Condensed Consolidated Statements of Loss and Comprehensive Loss

(All figures in U.S. dollars. Amounts are expressed in thousands except share and per share data.)

(Unaudited)

Three months ended June 30, Six months ended June 30,

2025 2026 2025 2026

Revenue:

Research fees $ 6,639 $ 3,901 $ 10,707 $ 12,021

Licensing and royalty revenue 10,445 149 10,613 341

Total revenue 17,084 4,050 21,320 12,362

Operating expenses:

Research and development(1)

39,213 45,987 81,711 92,649

Sales, general, and administrative(1)

21,986 13,850 41,054 26,185

Depreciation and amortization 5,470 6,990 10,801 13,828

Total operating expenses 66,669 66,827 133,566 132,662

Loss from operations (49,585) (62,777) (112,246) (120,300)

Other (income) expense:

Interest and other (9,549) 42 (15,073) (3,606)

Grants and incentives (3,692) (3,854) (7,845) (8,193)

Total other income (13,241) (3,812) (22,918) (11,799)

Loss before income tax (36,344) (58,965) (89,328) (108,501)

Income tax recovery (1,617) (3,538) (8,980) (9,909)

Net loss $ (34,727) $ (55,427) $ (80,348) $ (98,592)

Foreign currency translation adjustment 4,341 (733) 1,721 1,082

Comprehensive loss $ (30,386) $ (56,160) $ (78,627) $ (97,510)

Net loss per share

Basic $ (0.12) $ (0.18) $ (0.27) $ (0.32)

Diluted $ (0.12) $ (0.18) $ (0.27) $ (0.32)

Weighted-average common shares outstanding

Basic 298,508,601 305,557,294 298,105,760 304,329,623

Diluted 298,508,601 305,557,294 298,105,760 304,329,623

(1) Exclusive of depreciation and amortization

AbCellera Biologics Inc.

Condensed Consolidated Balance Sheets

(All figures in U.S. dollars. Amounts are expressed in thousands except share data.)

(Unaudited)

December 31, 2025 June 30, 2026

Assets

Current assets:

Cash and cash equivalents $ 128,513 $ 120,065

Marketable securities 405,313 420,039

Total cash, cash equivalents, and marketable securities 533,826 540,104

Accounts and accrued receivable 58,293 18,597

Restricted cash 25,000 25,000

Other current assets 111,113 95,529

Total current assets 728,232 679,230

Long-term assets:

Property and equipment, net 428,003 416,677

Intangible assets, net 38,381 36,530

Goodwill 47,806 47,806

Investments in equity accounted investees 62,580 65,229

Other long-term assets 51,948 62,103

Total long-term assets 628,718 628,345

Total assets $ 1,356,950 $ 1,307,575

Liabilities and shareholders' equity

Current liabilities:

Accounts payable and other current liabilities $ 50,781 $ 32,484

Deferred revenue 13,526 20,705

Total current liabilities 64,307 53,189

Long-term liabilities:

Operating lease liability 137,403 129,948

Deferred revenue 3,500 40,450

Deferred government contributions 174,453 178,254

Other long-term liabilities 10,383 9,714

Total long-term liabilities 325,739 358,366

Total liabilities 390,046 411,555

Commitments and contingencies

Shareholders' equity:

Common shares: no par value, unlimited authorized shares at December 31, 2025 and June 30, 2026: 300,600,710 and 306,469,632 shares issued and outstanding at December 31, 2025 and June 30, 2026, respectively

802,341 821,242

Additional paid-in capital 198,279 206,004

Accumulated other comprehensive loss (4,234) (3,152)

Accumulated deficit (29,482) (128,074)

Total shareholders' equity 966,904 896,020

Total liabilities and shareholders' equity $ 1,356,950 $ 1,307,575

AbCellera Biologics Inc.

Condensed Consolidated Statement of Cash Flows

(Expressed in thousands of U.S. dollars.)

(Unaudited)

Six months ended June 30,

2025 2026

Cash flows from operating activities:

Net loss $ (80,348) $ (98,592)

Cash flows from operating activities:

Depreciation of property and equipment 8,951 11,977

Amortization of intangible assets 1,851 1,851

Amortization of operating lease right-of-use assets 2,863 3,610

Stock-based compensation 28,993 24,299

Other 70 7,019

Changes in operating assets and liabilities:

Research fees and grants receivable (12,524) 25,367

Income taxes receivable (7,588) (8,024)

Accounts payable and accrued liabilities (7,356) (16,621)

Deferred revenue 9,361 44,129

Deferred grant income (1,681) (4,453)

Other assets 13,450 1,838

Net cash used in operating activities (43,958) (7,600)

Cash flows from investing activities:

Purchases of property and equipment (24,001) (5,963)

Purchase of marketable securities (291,542) (308,184)

Proceeds from marketable securities 303,437 293,557

Receipt of grant funding 6,448 6,955

Long-term investments and other assets (18,218) (105)

Net cash used in investing activities (23,876) (13,740)

Cash flows from financing activities:

Proceeds from deferred government contributions and other 2,595 13,585

Net cash provided by financing activities 2,595 13,585

Effect of exchange rate changes on cash and cash equivalents 1,351 (468)

Decrease in cash and cash equivalents (63,888) (8,223)

Cash and cash equivalents and restricted cash, beginning of period 183,615 155,249

Cash and cash equivalents and restricted cash, end of period $ 119,727 $ 147,026

Restricted cash included in other assets 2,290 1,961

Total cash, cash equivalents, and restricted cash shown on the balance sheet $ 117,437 $ 145,065

Supplemental disclosure of non-cash investing and financing activities

Property and equipment in accounts payable 12,733 979

Right-of-use assets obtained in exchange for operating lease obligation 69,787 –

Inquiries

Media: Tiffany Chiu; media@abcellera.com, +1(236)521-6774

Partnering: Murray McCutcheon, Ph.D.; partnering@abcellera.com, +1(604)559-9005

Investor Relations: Peter Ahn; ir@abcellera.com, +1(778)729-9116

Source: AbCellera Biologics Inc.

EX-99.2

Filename: a2026q2fybusinessupdatea.htm · Sequence: 3

a2026q2fybusinessupdatea

CO PY RI GH T © A BC EL LE RA AUGUST 5, 2026 Q2 2026 BUSINESS UPDATE

These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties, other factors, and definition of our business metrics are described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this document represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law. DISCLAIMER This document contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this document other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, plans, objectives for future operations, and the evaluation of our available liquidity to execute on our strategy (including our ability to access our reimbursement based R&D government contributions). The use of certain data derived from cross-study comparisons are not based on any head-to-head clinical trials. Cross-study comparisons are inherently limited and may suggest misleading similarities and differences and are presented for informational purposes. In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. 2 CO PY RI GH T © A BC EL LE RA Q2 2 02 6 B us in es s U pd at e

3 CO PY RI GH T © A BC EL LE RA Q2 2 02 6 Bu si ne ss U pd at e ABCL635 patient enrollment closed, Phase 2 readout in Q3, and all programs in the pipeline progressing 2026 PRIORITIES UPDATE Nominate at least 1 additional development candidate for IND-enabling activities ABCL635 Phase 2 clinical trial top-line readout in Q3 2026 ABCL575 Phase 1 clinical trial top-line readout in Q4 2026 ABCL688 progressing through IND-enabling activities ABCL386 progressing through IND-enabling activities Enrollment complete Dosing complete

4 CO PY RI GH T © A BC EL LE RA Q2 2 02 6 Bu si ne ss U pd at e We are using our TCE platform to advance programs into the clinical both internally and through strategic collaborations Novel TCE building blocks Proprietary panels of CD3-binding antibodies and costimulatory antibodies to fine- tune TCE function. A scalable process to assess TCE function Established tools, workflows, and high- throughput in vitro assays to systematically test hundreds of diverse molecules and multiple modalities. Experience across diverse targets Applying expertise and a deep understanding of TCE biology drawn from internal and partner- initiated bispecific programs on diverse targets and modalities. 2x1 T-CELL ENGAGER PLATFORM Our TCE platform is fully integrated with end-to-end capabilities, from discovery to manufacturing: Recent TCE deals are adding $112M in upfront cash to our balance sheet

5 CO PY RI GH T © A BC EL LE RA Q2 2 02 6 Bu si ne ss U pd at e Collaboration with Vertex to advance programs in autoimmunity PARTNERING: TCE COLLABORATIONS Multi-target collaboration in autoimmune disease and other conditions $28M Eligible for potential downstream payments and tiered royalties on net sales. total upfront payments OPTIONAL: SCOPE EXPANSION If mutually agreed, AbCellera could perform cell line development, process development, and clinical manufacturing through Phase 1.

6 CO PY RI GH T © A BC EL LE RA Q2 2 02 6 Bu si ne ss U pd at e Collaboration with Jazz to advance programs in oncology PARTNERING: TCE COLLABORATIONS 3 Discovery Programs OPTIONAL: PROGRAM EXPANSION 2 Additional Discovery Programs $2.5B ● $84M in total upfront payments ($56M of which received in Q2) Mid-single digit to low double digit tiered royalties on net sales. total potential payments $1.6B ● $56M in total potential upfront payments Mid-single digit to low double digit tiered royalties on net sales. total potential payments AbCellera could undertake certain IND-enabling activities and clinical manufacturing. OPTIONAL: SCOPE EXPANSION

7 CO PY RI GH T © A BC EL LE RA Q2 2 02 6 Bu si ne ss U pd at e We welcome Dr. Victor Sandor and Dr. Lynn Seely as independent directors to AbCellera’s board of directors Dr. Victor Sandor Dr. Lynn Seely

8 CO PY RI GH T © A BC EL LE RA Q2 2 02 6 Bu si ne ss U pd at e Q2 2026 FINANCIALS UPDATE

9 CO PY RI GH T © A BC EL LE RA Q2 2 02 6 Bu si ne ss U pd at e We continue to maintain a strong liquidity position to execute on our strategy * As of June 30, 2026 in total available government funding*~$110M in total cash balances & marketable securities*>$565M in available liquidity to execute on our strategy*>$675M

10 CO PY RI GH T © A BC EL LE RA Q2 2 02 6 Bu si ne ss U pd at e RESEARCH & DEVELOPMENT SALES, GENERAL & ADMIN Operating expenses reflect R&D investments Operating Expenses USDRevenue USD MILESTONES RESEARCH FEES LICENSING AND ROYALTY Q2 2025 Q2 2026 $17.1M $4.1M Q2 2025 Q2 2026 $39.2M $46.0M +$6.8M Q2 2025 Q2 2026 $22.0M $13.9M -$8.1M

11 CO PY RI GH T © A BC EL LE RA Q2 2 02 6 Bu si ne ss U pd at e Net loss of $55M; equivalent to ($0.18) per share (basic & diluted) Earnings USD NET EARNINGS EARNINGS PER SHARE: BASIC AND DILUTED Q2 2025 Q2 2026 ($34.7M) ($55.4M) Q2 2025 Q2 2026 ($0.12) ($0.18)

12 CO PY RI GH T © A BC EL LE RA Q2 2 02 6 Bu si ne ss U pd at e Over $565M in total cash balances and marketable securities Cash Flows USD * Restricted cash (including restricted cash in other assets)

13 CO PY RI GH T © A BC EL LE RA Q2 2 02 6 Bu si ne ss U pd at e THANK YOU

GRAPHIC

Filename: a2026q2fybusinessupdatea001.jpg · Sequence: 7

Binary file (44470 bytes)

Download a2026q2fybusinessupdatea001.jpg

GRAPHIC

Filename: a2026q2fybusinessupdatea002.jpg · Sequence: 8

Binary file (121394 bytes)

Download a2026q2fybusinessupdatea002.jpg

GRAPHIC

Filename: a2026q2fybusinessupdatea003.jpg · Sequence: 9

Binary file (90793 bytes)

Download a2026q2fybusinessupdatea003.jpg

GRAPHIC

Filename: a2026q2fybusinessupdatea004.jpg · Sequence: 10

Binary file (120901 bytes)

Download a2026q2fybusinessupdatea004.jpg

GRAPHIC

Filename: a2026q2fybusinessupdatea005.jpg · Sequence: 11

Binary file (77282 bytes)

Download a2026q2fybusinessupdatea005.jpg

GRAPHIC

Filename: a2026q2fybusinessupdatea006.jpg · Sequence: 12

Binary file (85627 bytes)

Download a2026q2fybusinessupdatea006.jpg

GRAPHIC

Filename: a2026q2fybusinessupdatea007.jpg · Sequence: 13

Binary file (70174 bytes)

Download a2026q2fybusinessupdatea007.jpg

GRAPHIC

Filename: a2026q2fybusinessupdatea008.jpg · Sequence: 14

Binary file (63137 bytes)

Download a2026q2fybusinessupdatea008.jpg

GRAPHIC

Filename: a2026q2fybusinessupdatea009.jpg · Sequence: 15

Binary file (82413 bytes)

Download a2026q2fybusinessupdatea009.jpg

GRAPHIC

Filename: a2026q2fybusinessupdatea010.jpg · Sequence: 16

Binary file (57374 bytes)

Download a2026q2fybusinessupdatea010.jpg

GRAPHIC

Filename: a2026q2fybusinessupdatea011.jpg · Sequence: 17

Binary file (47830 bytes)

Download a2026q2fybusinessupdatea011.jpg

GRAPHIC

Filename: a2026q2fybusinessupdatea012.jpg · Sequence: 18

Binary file (58753 bytes)

Download a2026q2fybusinessupdatea012.jpg

GRAPHIC

Filename: a2026q2fybusinessupdatea013.jpg · Sequence: 19

Binary file (63680 bytes)

Download a2026q2fybusinessupdatea013.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 21

v3.26.1

Cover

Aug. 05, 2026

Cover [Abstract]

Document Type

8-K

Entity Registrant Name

AbCellera Biologics Inc.

Document Period End Date

Aug. 05, 2026

Entity Incorporation, State or Country Code

Entity File Number

001-39781

Entity Address, Postal Zip Code

V5Y 1G6

Entity Central Index Key

0001703057

Amendment Flag

false

Entity Address, Address Line One

150 W 4th Avenue Vancouver, BC

Entity Address, City or Town

Vancouver

Entity Address, State or Province

City Area Code

(604)

Local Phone Number

559-9005

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common shares

Trading Symbol

ABCL

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration